SELENA+
AI Medical Screening
EyRIS Pte. Ltd.
Through EyRIS Pte. Ltd., Nova MSC Group brings clinically validated artificial intelligence into healthcare screening and early detection.
Overview
Artificial intelligence is transforming healthcare by making screening more scalable, efficient, and accessible. Through EyRIS Pte Ltd, Nova MSC Group brings this capability into real clinical use with SELENA+™, an advanced deep learning system designed for retinal image analysis and disease screening.
Developed with leading research institutions, SELENA+™ supports earlier detection of major eye diseases and helps healthcare providers scale screening programmes more effectively.
What SELENA+ Does
SELENA+ analyses retinal photographs to detect key eye conditions including diabetic retinopathy, glaucoma suspect, and age-related macular degeneration. By automating screening support, it helps providers identify at-risk patients earlier and improve referral and follow-up pathways.
The solution is designed for use in structured screening environments where consistency, speed, and scalability are important.
Key Capabilities
Deep Learning-Based Screening
Applies AI image analysis to support detection of major retinal disease indicators.
Multi-Disease Detection
Screens for more than one disease marker from the same retinal image set.
Scalable Screening Support
Helps healthcare systems screen larger patient populations more efficiently.
Consistent Output
Supports more standardised results, particularly in high-volume or resource-constrained settings.
Future Expansion Potential
Built on an architecture that can evolve to support additional algorithms and broader health indicators over time.
Why It Matters?
SELENA+ supports a more proactive model of care. Earlier detection can lead to earlier treatment, which is particularly important in reducing avoidable vision loss and improving long-term patient outcomes.
For healthcare systems, the technology helps improve efficiency and extends screening reach. For clinicians, it provides support in handling growing patient volumes. For patients, it can improve access to timely detection and intervention.
Who It Is For?
- Hospitals and eye centres
- National and regional screening programmes
- Primary care and outpatient screening networks
- Healthcare systems expanding preventive care initiatives
- Partners looking to deploy AI into real clinical workflows
Regional Track Record
EyRIS has established itself as a credible AI healthcare player through collaborations, regulatory progress, and deployments across multiple markets. SELENA+ reflects Nova MSC Group’s position at the intersection of healthcare, data science, and clinically relevant innovation.
Part of the Nova Group Ecosystem
SELENA+ strengthens Nova MSC Group’s healthcare offering by adding AI-driven screening to the wider ecosystem. It complements VESALIUS as the digital healthcare platform and supports the Group’s broader push into intelligent, scalable healthcare technologies.
Interested in scaling screening through AI?
Speak to us about how SELENA+ can support early detection and smarter screening programmes.